logo
  

RM Plc Q3 Trading Ahead Of View, Now Sees More Profit In H2; Stock Climbs

Shares of RM Plc. (RM.L) climbed around 14 percent in London trading after the educational IT and resources group said Wednesday that its trading in the third quarter has progressed ahead of expectations. RM now expects a significantly more profitable second half than expected earlier.

In its Interim Management Statement for the period from 1 June to 17 September, the company noted that the repositioning of the Education Technology division continues to proceed satisfactorily with costs running below plan. Lower costs than expected have also been incurred at the end of some long term managed service contracts. Profitability of the personal computing devices business, which is being wound down, has continued ahead of plan.

In the Education Resources division, good revenue growth and margin performance in TTS has continued ahead of expectations over recent months.

Further, the company said its Assessment and Data Services division, trading as RM Results, continues to trade in line with growth expectations.

As of August 31, net cash was 28.2 million pounds, compared with 38.3 million pounds a year earlier.

In London, RM shares were gaining 17.44 pence or 14.29 percent, and trading at 139.44 pence.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT